TSE:4502Pharmaceuticals
Takeda (TSE:4502) Stock Still Looks Slightly Undervalued Overall
Takeda Pharmaceutical stock has delivered an 83.5% return over the past five years, yet its current valuation checks paint a more nuanced picture that sits between clear bargain and clear premium.
Takeda Pharmaceutical's 83.5% five year return suggests shareholders have already seen substantial value creation built into today's share price.
The new AI driven drug discovery collaboration with Insilico Medicine can support expectations for the business over the longer term, while any setback...